Guardant Health shares are trading higher after the company partnered with Agostino Gemelli University Polyclinic Foundation to launch an in-house liquid biopsy testing service using Guardant360 CDx.
Portfolio Pulse from Benzinga Newsdesk
Guardant Health's stock is rising following a partnership with Agostino Gemelli University Polyclinic Foundation to introduce an in-house liquid biopsy testing service using Guardant360 CDx.
September 10, 2024 | 5:41 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Guardant Health's stock is experiencing an uptick due to a new partnership with Agostino Gemelli University Polyclinic Foundation. This collaboration will see the launch of an in-house liquid biopsy testing service using Guardant360 CDx, potentially expanding Guardant's market reach and enhancing its product utilization.
The partnership with a reputable institution like Agostino Gemelli University Polyclinic Foundation is likely to enhance Guardant Health's market presence and credibility. The use of Guardant360 CDx in this new service could lead to increased adoption and sales, positively impacting the stock price.
CONFIDENCE 95
IMPORTANCE 80
RELEVANCE 90